Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi

Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart fa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2020/09/01, Vol.59(17), pp.2155-2160
Hauptverfasser:	Tsujinaga, Shingo, Iwano, Hiroyuki, Oshino, Tomohiro, Kadosaka, Takahide, Mizuguchi, Yoshifumi, Motoi, Ko, Chiba, Yasuyuki, Koya, Taro, Temma, Taro, Kamiya, Kiwamu, Fukushima, Arata, Koizumi, Takuya, Sato, Tomoya, Takenaka, Sakae, Tada, Atsushi, Ishizaka, Suguru, Sarashina, Miwa, Omote, Kazunori, Kamada, Rui, Konishi, Takao, Sato, Takuma, Nagai, Toshiyuki, Yamashita, Hiroko, Anzai, Toshihisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - therapeutic use Aged Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Atrium Bevacizumab Bevacizumab - adverse effects Bevacizumab - therapeutic use Breast cancer Breast Neoplasms - drug therapy cardiotoxicity Case Report Chemotherapy Congestive heart failure Epirubicin Epirubicin - adverse effects Epirubicin - therapeutic use Female Heart failure Heart Failure - chemically induced Heart Failure - drug therapy Heart Failure - physiopathology Humans Internal medicine Monoclonal antibodies Targeted cancer therapy Thromboembolism thrombus Treatment Outcome Vascular endothelial growth factor Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!